Sign In
Buy ZLDPF
$49.02
+0 (+0%)
At Close: Jun 03, 2026
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going
09:51am, Thursday, 15'th Aug 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Rec
Zealand Pharma seeks big pharma partners for obesity drug candidate
03:45am, Thursday, 15'th Aug 2024
Denmark's Zealand Pharma is set to start talks in the second half of this year with other pharmaceutical companies for potential partnerships to develop and commercialize its weight-loss drug petrelin
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
11:00am, Monday, 12'th Aug 2024
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
11:00am, Monday, 29'th Jul 2024
Press release – 7 / 2024 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Copenhagen, Denmark, 29 July 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biot
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
08:45am, Monday, 24'th Jun 2024
Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
Weight loss drug contender Zealand Pharma jumps 23% on trial results
05:58am, Friday, 21'st Jun 2024
Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide. The company said petrelintide may produce similar weight loss results and a "better
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
04:55am, Friday, 21'st Jun 2024
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drug
Zealand Pharma's drug reduces weight by 8.6% in early-stage study
11:57am, Thursday, 20'th Jun 2024
Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6% after 16 weekly doses.
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Bo
Zealand Pharma says drug shows improvement in fatty liver disease patients
09:04am, Thursday, 06'th Jun 2024
Denmark's Zealand Pharma said on Thursday its experimental weight-loss drug showed an improvement in patients with a type of fatty liver disease after results from a mid-stage study were leaked, sendi
Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript
11:37am, Thursday, 16'th May 2024
Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2024 Results Conference Call May 16, 2024 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO David Kendall - CMO Henriette We
Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment
07:00pm, Thursday, 21'st Mar 2024
Positive results achieved in phase 2 study using survodutide for the treatment of patients with MASH; Primary endpoint of histological improvement of MASH met with statistical significance. The global
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
05:15am, Thursday, 14'th Mar 2024
Novo Nordisk's $600 billion valuation makes it one of the top healthcare companies in the world. For investors looking for stocks with more upside, upstart Zealand Pharma may fit the bill.
Zealand Pharma CEO: Magnitude of obesity pandemic requires many more solutions
12:00pm, Friday, 01'st Mar 2024
Adam Steensberg, Zealand Pharma CEO, joins 'Money Movers' to discuss the goal for the company's weight loss drugs, the company's drug around liver disease, and more.
